Ranitidine and Bladder transitional cell carcinoma - a phase IV clinical study of FDA data

Summary:

Bladder transitional cell carcinoma is reported as a side effect among people who take Ranitidine (ranitidine), especially for people who are male, 60+ old, have been taking the drug for 10+ years also take Aspirin, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Bladder transitional cell carcinoma when taking Ranitidine. It is created by eHealthMe based on reports of 233,168 people who have side effects when taking Ranitidine from the FDA, and is updated regularly.

What is Ranitidine?

Ranitidine has active ingredients of ranitidine. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 234,475 Ranitidine users. Check the latest studies of Ranitidine.

What is Bladder transitional cell carcinoma?

Bladder transitional cell carcinoma (types of bladder cancer) is found to be associated with 200 drugs and 229 conditions by eHealthMe. Check the latest studies of Bladder transitional cell carcinoma.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

233,168 people reported to have side effects when taking Ranitidine.
Among them, 16 people (0.01%) have Bladder transitional cell carcinoma.

Could Ranitidine cause Bladder transitional cell carcinoma?

Among these 16 people:

How long have people been on Ranitidine when they have Bladder transitional cell carcinoma? *

What is the gender of people who have Bladder transitional cell carcinoma when taking Ranitidine? *

female: 13.33 %
male: 86.67 %

What is the age of people who have Bladder transitional cell carcinoma when taking Ranitidine? *

What are other drugs people take besides Ranitidine? *

Aspirin: 7 people, 43.75%
Zantac: 4 people, 25.00%
Plavix: 3 people, 18.75%
Dexamethasone: 3 people, 18.75%
Metformin: 3 people, 18.75%
Synthroid: 3 people, 18.75%
Amlodipine: 2 people, 12.50%
Terazosin Hydrochloride: 2 people, 12.50%
Zofran: 2 people, 12.50%
Benadryl: 2 people, 12.50%

What are other side effects people have besides Bladder transitional cell carcinoma? *

Haematuria (presence of blood in urine): 4 people, 25.00%
Bladder Cancer: 4 people, 25.00%
Bladder Mass: 3 people, 18.75%
Abdominal Pain Upper: 2 people, 12.50%
Sinusitis (inflammation of sinus): 2 people, 12.50%
Heart Attack: 2 people, 12.50%
Cellulitis (infection under the skin): 2 people, 12.50%
Pneumonia: 2 people, 12.50%
Bladder Neoplasm (bladder tumour): 2 people, 12.50%
Bladder Disorder: 2 people, 12.50%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 6 people, 37.50%
High Blood Pressure: 3 people, 18.75%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 18.75%
Acute Coronary Syndrome (acute chest pain and other symptoms that happen because the heart does not get blood): 2 people, 12.50%
Throat Irritation: 1 person, 6.25%
Bone Disorder: 1 person, 6.25%
Diabetes: 1 person, 6.25%
Flatulence (flatus expelled through the anus): 1 person, 6.25%
Gastritis (inflammation of stomach): 1 person, 6.25%
High Blood Cholesterol: 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Ranitidine and have Bladder transitional cell carcinoma?

- Check whether Bladder transitional cell carcinoma is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ranitidine:

Ranitidine (234,475 reports)

Browse all side effects of Ranitidine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bladder transitional cell carcinoma:

Bladder transitional cell carcinoma (200 drugs)

Browse all the conditions that are associated with Bladder transitional cell carcinoma:

Bladder transitional cell carcinoma (229 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ranitidine (the active ingredients of Ranitidine) and Ranitidine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.